Andreea Corina, Maria B. Abrudan, Dragana Nikolic*, Adriana F. Cӑtoi, Roberta Chianetta, Giuseppa Castellino, Roberto Citarrella, Anca P. Stoian, Pablo Pérez-Martínez and Manfredi Rizzo Pages 3704 - 3714 ( 11 )
The prevalence of several diseases increases by age, including cardiovascular diseases, which are the leading cause of morbidity and mortality worldwide. Aging, as a complex process characterized by senescence, triggers various pathways, such as oxidative stress, systemic inflammation, metabolism dysfunction, telomere shortening, mitochondrial dysfunction and deregulated autophagy. A better understanding of the mechanisms underlying senescence may lead to the development of new therapeutic targets and strategies for age-related pathologies and extend the healthy lifespan. Modulating lifestyle risk factors and adopting healthy dietary patterns remain significant tools in delaying the aging process, decreasing age-associated comorbidities and mortality, increasing life expectancy and consequently, preventing the development of cardiovascular disease. Furthermore, such a strategy represents the most cost-effective approach, and the quality of life of the subjects may be significantly improved. An integrated, personalized approach targeting cardiometabolic aging and frailty is suggested in daily clinical practice. However, it should be initiated from an early age. Moreover, there is a need for further well designed and controlled studies in order to elucidate a link between the time of feeding, longevity and cardiovascular prevention. In the future, it is expected that the pharmacological treatment in cardioprotective management will be necessary, accompanied by equally important lifestyle interventions and adjunctive exercise.
Aging, diet, cardioprotection, cardiovascular risk, diabetes, metabolic syndrome, nutraceuticals.
Lipids and Atherosclerosis Research Unit, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Department of Pharmaceutical Technology and Biopharmaceutics, "Iuliu Hațieganu", University of Medicine and Pharmacy, Faculty of Pharmacy, Cluj-Napoca, PROMISE Department, University of Palermo, Palermo, Pathophysiology Department, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, PROMISE Department, University of Palermo, Palermo, PROMISE Department, University of Palermo, Palermo, PROMISE Department, University of Palermo, Palermo, Department of Diabetes, Nutrition and Metabolic Diseases, Carol Davila University of Medicine and Pharmacy, Bucharest, Lipids and Atherosclerosis Research Unit, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, PROMISE Department, University of Palermo, Palermo